165 related articles for article (PubMed ID: 19961662)
1. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications.
Panagiotopoulos C; Ronsley R; Davidson J
Can J Psychiatry; 2009 Nov; 54(11):743-9. PubMed ID: 19961662
[TBL] [Abstract][Full Text] [Related]
2. Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics.
de Hoogd S; Overbeek WA; Heerdink ER; Correll CU; de Graeff ER; Staal WG
J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):166-73. PubMed ID: 22506734
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study.
Ilies D; Huet AS; Lacourse E; Roy G; Stip E; Amor LB
Can J Psychiatry; 2017 Dec; 62(12):827-836. PubMed ID: 28673098
[TBL] [Abstract][Full Text] [Related]
4. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
[TBL] [Abstract][Full Text] [Related]
5. Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Ronsley R; Nguyen D; Davidson J; Panagiotopoulos C
Can J Psychiatry; 2015 Oct; 60(10):441-50. PubMed ID: 26720191
[TBL] [Abstract][Full Text] [Related]
6. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics.
Panagiotopoulos C; Ronsley R; Kuzeljevic B; Davidson J
Can J Psychiatry; 2012 Jan; 57(1):34-44. PubMed ID: 22296966
[TBL] [Abstract][Full Text] [Related]
7. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
[TBL] [Abstract][Full Text] [Related]
8. Quetiapine treatment in youth is associated with decreased insulin secretion.
Ngai YF; Sabatini P; Nguyen D; Davidson J; Chanoine JP; Devlin AM; Lynn FC; Panagiotopoulos C
J Clin Psychopharmacol; 2014 Jun; 34(3):359-64. PubMed ID: 24633003
[TBL] [Abstract][Full Text] [Related]
9. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics.
Patel NC; Hariparsad M; Matias-Akthar M; Sorter MT; Barzman DH; Morrison JA; Stanford KE; Strakowski SM; DelBello MP
J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):303-11. PubMed ID: 17630864
[TBL] [Abstract][Full Text] [Related]
10. Greater Arterial Stiffness in Children with or without Second-generation Antipsychotic Treatment for Mental Health Disorders: Rigidité Artérielle Plus Importante Chez Les Enfants Avec ou Sans Traitement Par Antipsychotiques de la Deuxième Génération Pour des Troubles de Santé Mentale.
Henderson AM; Islam N; Sandor GGS; Panagiotopoulos C; Devlin AM
Can J Psychiatry; 2021 Jul; 66(7):667-676. PubMed ID: 34180273
[TBL] [Abstract][Full Text] [Related]
11. Risperidone But Not Quetiapine Treatment Is Associated With Increased Appetite But Not Satiety Hormones in Children During An Oral Glucose Tolerance Test: A Pilot Study.
Ngai YF; Devlin AM; Panagiotopoulos C
J Clin Psychopharmacol; 2018 Dec; 38(6):622-626. PubMed ID: 30300290
[TBL] [Abstract][Full Text] [Related]
12. Initial screening of children treated with second-generation antipsychotics points to an association between physical activity and insulin resistance.
Cote AT; Devlin AM; Panagiotopoulos C
Pediatr Exerc Sci; 2014 Nov; 26(4):455-62. PubMed ID: 25372380
[TBL] [Abstract][Full Text] [Related]
13. Diet and cardiometabolic side effects in children treated with second-generation antipsychotics.
Barker MK; Sable CM; Montgomery SE; Chow L; Green TJ; Panagiotopoulos C; Devlin AM
Clin Nutr ESPEN; 2018 Feb; 23():205-211. PubMed ID: 29460800
[TBL] [Abstract][Full Text] [Related]
14. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre.
Tarricone I; Casoria M; Gozzi BF; Grieco D; Menchetti M; Serretti A; Ujkaj M; Pastorelli F; Berardi D
BMC Psychiatry; 2006 Mar; 6():11. PubMed ID: 16542430
[TBL] [Abstract][Full Text] [Related]
15. Metabolic monitoring for patients treated with antipsychotic medications.
Cohn TA; Sernyak MJ
Can J Psychiatry; 2006 Jul; 51(8):492-501. PubMed ID: 16933586
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study.
Mackin P; Watkinson HM; Young AH
Diabetologia; 2005 Feb; 48(2):215-21. PubMed ID: 15688206
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
18. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment.
Sjo CP; Stenstrøm AD; Bojesen AB; Frølich JS; Bilenberg N
J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):884-891. PubMed ID: 28783382
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance and impaired glucose tolerance in overweight and obese Costa Rican schoolchildren.
Holst-Schumacher I; Nuñez-Rivas H; Monge-Rojas R; Barrantes-Santamaría M
Food Nutr Bull; 2008 Jun; 29(2):123-31. PubMed ID: 18693476
[TBL] [Abstract][Full Text] [Related]
20. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
